PacBio To Begin Commercial Shipment of Revio Systems

Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK, Calif., March 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.